Intellectual Property - August 23, 2023
BioArctic receives patent in Japan
The Japanese Patent Office (JPO) is granting a new drug substance patent for the antibody BAN0805, invented by BioArctic as a potential treatment of Parkinson’s disease. The patent will expire in 2041, with the possibility of a patent term extension up until 2046. The aim is to develop a treatment that halts or slows the […]
Intellectual Property - August 9, 2023
InDex Pharmaceuticals has been granted a new patent
The company has announced that a new formulation patent for the drug candidate cobitolimod has been granted by the European Patent Office. The patent provides protection of the enema formulation of cobitolimod, that is currently under evaluation in the ongoing phase III program CONCLUDE. The patent will provide an exclusivity period until September 2042, with […]
Business - July 3, 2023
Orexo wins patent litigation in the US
The US District Court for the District of New Jersey ruled in favor of Orexo in its patent litigation against Sun Pharmaceutical Industries Limited, Sun Pharma Global FZE, Sun Pharma Global, Inc., and Sun Pharmaceutical Industries, Inc. (collectively “Sun”) regarding ZUBSOLV (buprenorphine and naloxone) sublingual tablets (CIII) in the US. The district court found that […]
Intellectual Property - May 22, 2023
AlzeCure is granted European patent
AlzeCure Pharma has announced that the European Patent Office (EPO) has granted a patent covering the company’s candidate drug ACD856, which is developed against Alzheimer’s disease and other disorders with cognitive impairment. “This is another key step for ACD856, given that we have previously also been granted a US patent for this substance. This further […]
Intellectual Property - April 19, 2023
OnDosis’ first patent issued by the United States Patent and Trademark Office
The issued patent covers the Dosage Manager device platform developed by OnDosis for dosing of oral solid medicines in the form of pellets. The issued patent is the first relating to OnDosis device and its core design and functionality, and the company expects further patents to follow in due course from the company’s extensive patent […]
Intellectual Property - April 18, 2023
Gedea Biotech obtains US patent
The United States Patent and Trademark Office (USPTO) has granted the company’s patent application directed to gluconic acid derivatives for preventing and/or treating bacterial infections. “The US patent covering treatment and prevention of vaginal bacterial infections by GDL, or pHyph, strengthens Gedea’s position in one of the largest markets for treatment of these conditions. pHyph […]
